Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer
Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer
Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV? patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.
Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).
Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).
Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.
134-137
Gilbert, Duncan C.
81232f2c-a6d5-4a5d-9df2-c38db6d2130c
Serup-Hansen, Eva
82661552-534e-430c-8f71-28dc6f9bfdc9
Linnemann, Dorte
65a35a9a-b8a8-491c-b80d-33930384ec40
Høgdall, Estrid
d8cfe122-fd87-477f-8c02-9215e7b7e0b0
Bailey, Charles
f96d0505-88f8-4e33-be8f-ebe926dc14a3
Summers, Jeff
32543e27-9ea4-4760-bd40-c73a34f54652
Havsteen, Hanne
986bfb6d-9e9a-434a-b05c-c1b68bf331fa
Thomas, Gareth J.
2ff54aa9-a766-416b-91ee-cf1c5be74106
Gilbert, Duncan C.
81232f2c-a6d5-4a5d-9df2-c38db6d2130c
Serup-Hansen, Eva
82661552-534e-430c-8f71-28dc6f9bfdc9
Linnemann, Dorte
65a35a9a-b8a8-491c-b80d-33930384ec40
Høgdall, Estrid
d8cfe122-fd87-477f-8c02-9215e7b7e0b0
Bailey, Charles
f96d0505-88f8-4e33-be8f-ebe926dc14a3
Summers, Jeff
32543e27-9ea4-4760-bd40-c73a34f54652
Havsteen, Hanne
986bfb6d-9e9a-434a-b05c-c1b68bf331fa
Thomas, Gareth J.
2ff54aa9-a766-416b-91ee-cf1c5be74106
Gilbert, Duncan C., Serup-Hansen, Eva, Linnemann, Dorte, Høgdall, Estrid, Bailey, Charles, Summers, Jeff, Havsteen, Hanne and Thomas, Gareth J.
(2016)
Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
British Journal of Cancer, 114 (2), .
(doi:10.1038/bjc.2015.448).
(PMID:26730577)
Abstract
Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for p16. Compared with HPV? patients, those with HPV+ disease generally show improved survival, although relapse rates around 25% indicate a need for further stratification of this group.
Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-infiltrating lymphocytes (TILs).
Results: Tumour-infiltrating lymphocyte scores were used to stratify p16+ cases, where tumours with absent/low levels of TIL had a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P=0.006).
Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides evidence of the clinical importance of the immune response.
Text
2016 Tumour infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.pdf
- Version of Record
More information
Accepted/In Press date: 30 November 2015
e-pub ahead of print date: 5 January 2016
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 395569
URI: http://eprints.soton.ac.uk/id/eprint/395569
ISSN: 0007-0920
PURE UUID: 994d66c4-9aff-4a4d-adad-cd64f064709f
Catalogue record
Date deposited: 01 Jun 2016 13:35
Last modified: 15 Mar 2024 00:43
Export record
Altmetrics
Contributors
Author:
Duncan C. Gilbert
Author:
Eva Serup-Hansen
Author:
Dorte Linnemann
Author:
Estrid Høgdall
Author:
Charles Bailey
Author:
Jeff Summers
Author:
Hanne Havsteen
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics